IFNG and cervical carcinoma: Gableh et al. (2016) claimed that the use of α-GalCer as an adjuvant in the DNA of the proposed cervical cancer vaccine increased lymphocyte proliferation, IFN-γ and IL-12 cytokine levels, and inhibited tumor growth [23].